Controller, FP&A, and audit-readiness for life-sciences companies from first close to the clinic. Burn, runway, and board reporting handled end to end, so your team stays at the bench.
Board snapshot · illustrative
Diligence-readyDoes the cash reach the readout?
Levent CorbaciFounder,Accel Financials
Works inside your stack
Who I work with
Services
Engagements are scoped to your stage and team, so you can focus on driving science while the numbers are handled with rigor.
Controller
From day-to-day bookkeeping to full controller functions. I implement the systems, close process, and internal controls that keep your data accurate, current, and investor-ready as you scale from seed to clinical stage and beyond.
Strategic FP&A
Go beyond balancing the books. Burn-rate analysis, cash-runway extension, scenario planning, and clinical trial cost forecasting, all tuned to the milestones your board actually cares about.
Audit & diligence readiness
Audit readiness should never be a fire drill. I keep your records compliant and diligence-ready, whether that's a year-end audit, a Series B data room, or an unexpected investor request.
How it works
No long onboarding, no mystery. A clear diagnosis, a defined build, then a monthly rhythm your board can set its watch by.
A focused review of your books, systems, burn, and upcoming milestones. You get a written assessment with priorities, not a sales deck.
Close process, controls, chart of accounts, and the operating model that turns raw ledger data into runway, scenarios, and board metrics.
A predictable monthly rhythm: close, variance review, runway update, board package. Diligence-ready every single month.
Every month
Systems & software
The stack most Cambridge biotechs already run, or should. I work inside it rather than around it.
17
tools
4
layers
POs, bills, cards and expenses: where cash leaves.
People costs, benefits and the cap table.
The system of record everything posts to.
Posts in from
Feeds
Where the ledger becomes runway, scenarios and board numbers.
Built on
Planning, in 40 seconds
Plan the year from the work, close every month against it, reforecast when the science moves, and read the result as cash against the calendar. Here is the whole loop for one illustrative company.
Scene 1 of 6
A budget starts with each trial, batch and hire, priced and placed in the month it happens. Not last year's spend plus ten percent.
An illustrative company. The numbers are invented; the mechanics are real.
Runway lab
Drag the sliders. A disciplined operating plan doesn't just tidy the books, it moves the date the money runs out, and whether you're raising from strength or necessity.
Cash runway · months
Your inputs
Illustrative and linear on purpose. Real models layer CRO milestones, hiring plans, and non-dilutive funding. Want yours built?
Build my real modelFree template
Bottom-up burn from headcount, CRO budgets, CMC batches, and recurring opex. Shifts every trial and the readout together when enrollment slips, and shows cash at readout and runway after readout, which is the number your board actually cares about.
Two-minute self-assessment
Twelve questions a first-audit team will ask, scored and ranked. You get the fixes on the spot; nothing is stored unless you send it.
Take the scorecard12
questions a first-audit team will ask
2 min
to answer, with the fixes on the spot
Private
nothing is stored unless you send it
About
I work where the ledger meets the boardroom.
For more than a decade I have worked inside the Cambridge biotech ecosystem, helping founders turn burn, runway, and operating data into numbers they can make decisions on.
I've sat inside the finance function at every stage from first close to clinical trials. That means I know which controls matter at seed, which models the board expects at Series B, and which questions auditors and investors will ask before they ask them.
Education
Stages worked across
Industry watch
Headlines from the SEC, FASB watchers, and the biotech trade press, filtered for what a finance team actually needs to know. Refreshed hourly.
Big Four accounting firms in comment letters urged the Securities and Exchange Commission (SEC) to approve the Public Company Accounting …
Updated Oct 22, 11:29 PM EDT · refreshes hourly
Selected automatically from public feeds. Links open the original publisher.
Contact
Tell me where the company is, from pre-seed to heading into an audit, and what's keeping you up at night.
What happens next
You send a few lines
Where the company is and what's pressing. Two sentences is plenty.
I reply within a business day
With a point of view on what to fix first, not a pitch.
A free 30-minute call
If it's a fit we scope the work. If not, you leave with next steps.
Levent Corbaci
Founder,Accel Financials
